The allocation and use of Developmental Funds has been managed centrally. Developmental Funds at UPCI have been utilized in two w/ays: 1) New Investigator and Program Support, to enhance research areas that have been identified in the strategic planning process as high priority for development and expansion;and 2) Pilot funding of UPCI member projects deemed by an internal advisory committee to be the most meritorious scientifically and likely to facilitate interactions among program members or to lead to subsequent success in obtaining major external funding. These developmental funds have been extremely helpful to vigorously promote the high priority goals of UPCI. The review of this funding category at the last competitive renewal ofthe CCSG rated it as having Excellent to Outstanding merit. Following the same approach that has been quite successful to date, it is proposed that the majority of funds being requested will be utilized to support recruitment in high priority areas for ongoing development and expansion. To a lesser extent, Developmental Funds will be used to fund pilot projects that explore innovative ideas and develop new collaborations as well as to enhance the capability of shared facilities to a lesser extent. We are requesting $278,079 towards faculty development, $200,000 for pilot projects and $100,000 for shared facilities development.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-25
Application #
8519319
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
25
Fiscal Year
2013
Total Cost
$476,733
Indirect Cost
$69,738
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4

Showing the most recent 10 out of 1187 publications